Sertraline: An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder

CNS Drugs

Volumn 7, Issue 6, 1997, Pages 480-500

  Perry, Caroline M ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OBSESSION; PRIORITY JOURNAL; REVIEW;

EID: 0030849917     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707060-00008     Document Type: Review

References (123)

1. Davis R, Wilde MI. Sertraline: a pharmacoeconomic evaluation of its use in depression. PharmacoEconomics 1996 Oct; 10: 409-31
2. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46: 36-44
3. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577-85
4. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990; 147 (9): 1209-15
5. Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder [abstract]. Annual Meeting of the Americal College of Neuropsychopharmacology; 1993 Dec 13-17; Honolulu
6. Montgomery SA, McIntyre A, Osthereider M, et al. A double-blind placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive compulsive disorder. Eur Neuropsychopharmacol 1993; 3: 143-52
7. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 559-67
8. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993; 16 (4): 749-66
9. Murdoch D, McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992 Oct; 44: 604-24
10. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive compulsive dsorder in five U.S. communities. Arch Gen Psychiatry 1988; 45: 1094-9
11. Hollander E, Fay M, Cohen B, et al. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioural findings. Am J Psychiatry 1988; 145: 1015-7
12. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987; 22: 677-87
13. Pigott TA. OCD: where the serotonin selectivity story begins. J Clin Psychiatry 1996; 57 Suppl. 6: 11-20
14. Barr LC, Goodman WK, Price LH. The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol 1993 Nov; 8 Suppl. 2: 79-82
15. Dolberg OT, Iancu I. Sasson Y, et al. The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 1996 Apr; 19: 129-47
16. Warneke L. Anxiety disorders. Focus on obsessive-compulsive disorder. Can Fam Phys 1993 Jul; 39: 1612-21
17. Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 1987; 44: 946-51
18. Murphy DL, Zohar J, Benkelfat C, et al. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry 1989; 155 Suppl. 8: 15-24
19. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996; 57 Suppl. 4: 9-13
20. Grimsley SR, Jann MW, Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11 (11): 930-57
21. Hoffman BJ, Mezey E, Brownstein MJ. Cloning of a serotonin transporter affected by antidepressants. Science 1991; 254: 579-80
22. Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990 Dec; 51 Suppl. B: 13-7
23. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996 Apr; 14: 225-31
24. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 1993 Jul; 14: 262
25. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49 (Suppl.): 46-51
26. Kovachich GB, Aronson CE, Brunswick DJ. Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology 1992 Dec; 7: 317-24
27. O'Donnell JM, Grealy M. Neuroendocrine response to clonidine and 8-OH-DPAT in rats following chronic administration of desipramine or sertraline. Br J Pharmacol 1992 Apr; 105: 863-8
28. 2adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology 1993 Jan; 8: 57-65
29. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994 Mar; 9 Suppl. 1: 19-26
30. Narita N, Hashimoto K, Tomitaka S-I, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain. Eur J Pharmacol 1996 Jun 20; 307: 117-9
31. Lightowler S, Kennett GA, Tulloch IF, et al. An investigation of the acute effects of sertraline in a rat social interaction test [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec. issue: 277
32. Walker JM, Bowen WD, Walker FO, et al. Sigma receptors: biology and function. Pharmacol Rev 1990; 42 (4): 355-402
33. Bergeron R, Debonnel G, De Montigny C. Modification of the N-methyl-D-aspartate response by antidepressant σ receptor ligands. Eur J Pharmacol 1993 Aug 24; 240: 319-23
34. Giardino L, Zanni M, Velardo A, et al. Effect of sertraline treatment on benzodiazepine receptors in the rat brain. J Neural Transm 1993; 94 (1): 31-41
35. Giardino L, Zanni M, Bettelli C, et al. Regulation of glutamic acid decarboxylase mRNA expression in rat brain after sertraline treatment. Eur J Pharmacol 1996; 312: 183-7
36. Hindmarch I, Bhatti JZ. Psychopharmacological effects of sertraline in normal healthy volunteers. Eur J Clin Pharmacol 1988; 35: 221-3
37. Hindmarch I, Shillingford J, Shillingford C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990 Dec; 51 Suppl. B: 34-6
38. Saletu B, Grünberger J. Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects. J Clin Psychiatry 1988; 49 Suppl.: 59-71
39. Mattila MJ, Saarialho-Kere U, Mattila M. Acute effects of sertraline, amitriptyline and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 1988; 49 Suppl.: 52-8
40. Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 1996; 3: 75-83
41. Louie AK, Lannon RA, Ajari LJ. Wilhdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994 Mar; 151: 450-1
42. Kent LSW, Laidlaw JDD. Suspected congenital sertraline dependence. Br J Psychiatry 1995 Sep; 167: 412-3
43. Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 1995 Oct; 15: 374-5
44. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993 Mar; 24: 203-20
45. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996 Apr; 78: 203-8
46. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991 Dec; 6 Suppl. 2: 11-21
47. Alderman J, Wolkow R, Johnston H, et al. Sertraline treatment in children and adolescents: tolerability, efficacy and pharmacokinetics [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 11
48. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in out-patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995 Apr; 52: 289-95
49. Ronfeld RA, Wilner KD, Baris BA. Sertraline: chronopharmacokinetics and the effect of coadministration with food. Clin Pharmacokinet 1997; 32 Suppl. 1: 50-5
50. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 Suppl. 1: 22-30
51. Altshuler LL, Burt VK, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995 Jun; 56: 243-5
52. Baum AL, Misri S. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harvard Rev Psychiatry 1996 Sep-Oct; 4: 117-25
53. Harvey A, Preskorn S, Lane R, et al. Sertraline and P4503A3/4 [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 40
54. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Then 1996; 60 (5): 512-21
55. LeBel M, Turgeon J. Vallée F, et al. Genetic determinant of sertraline (S) and fluoxetine (F) disposition in 20 healthy volunteers [abstract]. Pharm Res 1995 Sep; 12 Suppl.: S374
56. Wilner KD, Baris BA, Foulds GH, et al. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 41
57. Schwenk MH, Verga MA, Wagner JD, Hemodialyzability of sertraline. Clin Nephrol 1995 Aug; 44: 121-4
58. Tremaine LM, Joerg EA. Automated gas chromatographic electron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989 Nov 24; 496: 423-9
59. Démolis J-L, Angebaud P, Grangé J-D, et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996 Sep; 42: 394-7
60. Wilner KD, Everson G, Foulds GH, et al. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 40-1
61. Wilner KD, Everson G, Foulds GH, et al. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment [poster]. XXth Collegium Internationale Neuro-Psychopharmacologicum; 1996 Jun 23-27; Melbourne
62. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Pan II. J Clin Psychopharmacol 1996 Oct; 16: 345-55
63. Salzman C. Heterogeneity of SSR1 response. Harv Rev Psychiatry 1996 (4): 215-7
64. Sproule BA, Otton SV, Cheung SW, et al. Does sertraline inhibit CYP2D6 after chronic dosing? [abstract]. Clin Pharmacol Ther 1995 Feb: 57: 151
65. Lane RM. Pharmacokinetics drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11 Suppl. 5: 31-61
66. Gardner MJ, Baris BA, Wilner KD, et al. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997; 32 Suppl. 1: 43-9
67. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997; 32 Suppl. 1: 31-6
68. March JS, Leonard HL, Swedo SE. Pharmacotherapy of obsessive-compulsive disorder. Child Adolesc Psychiatr Clin North Am 1995; 4 (1): 217-36
69. Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994 Dec; 28: 1359-69
70. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996: 57 Suppl. 1: 24-8
71. Apseloff G, Wilner KD, Gerber N, et al. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997; 32 Suppl. 1: 37-42
72. MacKay ES, Carson SW, Grimsley S, et al. Effects of sertraline on steady-state serum concentrations of imipramine and its metabolites [abstract]. Pharmacotherapy 1994 May-Jun; 14: 368
73. Rapeport WG, Coates PE, Dewland PM. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry 1996; 57 Suppl. 1: 16-9
74. Apseloff G, Wilner KD, von Deutsch DA, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992; 32: 643-6
75. Ziegler MG, Wilner KD. Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry 1996; 57 Suppl. 1: 12-5
76. Zohar J, Zohar-Kadouch RC, Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992 Feb; 43: 210-8
77. Lydiard RB. Obsessive-compulsive disorder: a new perspective in diagnosis and treatment. Int Clin Psychopharmacol 1994 Jun; 9 Suppl. 3: 33-7
78. McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990 Jan; 39: 136-53
79. Goodman WK, Price LH, Rasmusson SA, et al. The Yale-Brown Obsessive Compulsive Scale II. Validity. Arch Gen Psychiatry 1989 Nov; 46: 1012-6
80. Goodman WK, Price LH, Rasmusson SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use and reliability. Arch Gen Psychiatry 1989 Nov; 46: 1006-11
81. American Psychiatric Association. DSM-III: diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
82. American Psychiatric Association. DSM-III-R: diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
83. Chouinard CJ, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990; 26 (3): 279-84
84. Kronig MH, Apter J, Asnis G, et al. A multicenter trial of sertraline for obsessive-compulsive disorder [poster]. 33rd American College of Neuropsycholopharmacology; 1995 Dec 12-16; San Juan, 38-9
85. Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995 Jun; 10: 57-65
86. Rasmussen S, Hackett E, DuBoff E, et al. Long-term sertraline treatment of obsessive compulsive disorder: a 2 year study [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec. issue: 373
87. Bisserbe J-C, Lane RM, Flament M, et al. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997; 12: 82-97
88. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730-8
89. Rasmussen S, Hackett E, DuBoff J, et al. A two-year study of sertraline in the treatment of obsessive compulsive disorder. Pfizer Inc. New York, NY, USA 1996. (Data on file)
90. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995 Jan; 52: 53-60
91. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995 Apr; 166: 424-43
92. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995 Mar: 10: 11-8
93. Rasmussen S, Baer L, Shera D. Previous SRI treatment and efficacy of sertraline for OCD: combined analysis of 4 multicenter trials. Pfizer Inc. New York, NY, USA. 1997. (Data on file)
94. Bradford JM, Greenberg D, Gojer J. et al. Sertraline in the treatment of pedophilia: an open label study [poster]. 148th American Psychiatric Association; 1995 May 20-25; Miami
95. American Psychiatric Association. Paraphilias. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
96. Kafka MP. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 1994; 6 (3): 189-95
97. Stein DJ, Hollander E, Josephson SC. Serotonin reuptake blockers for the treatment of obsessional jealousy. J Clin Psychiatry 1994 Jan; 55: 30-3
98. Roberts JM, Lydiard RB. Sertraline in the treatment of bulimia nervosa [letter]. Am J Psychiatry 1993 (150): 1753
99. Frankenburg FR, Kando JC. Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome. J Clin Psychopharmacology 1994; 14 (5): 359-60
100. Bradford JM, Gratzer TG. A treatment for impulse control disorders and paraphilia: a case report. Can J Psychiatry 1995 Feb; 40: 4-5
101. Rahman MA, Gregory R. Trichotillomania associated with HIV infection and response to sertraline. Psychosomatics 1995 Jul-Aug; 36: 417-8
102. Bisserbe JC, Lane R. Sertraline in obsessive-compulsive spectrum disorders: a case study series [abstract]. Fur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 112
103. Wolkow R, Alderman J. Johnston H, et al. Sertraline treatment of children and adolescents with obsessive compulsive disorder or depression [poster]. World Congress of Psychiatry; 1996 Aug 23-28; Madrid
104. Wolkow R, Marach J, Safferman A, et al. A placebo-controlled trial of sertraline treatment for pediatric obsessive compulsive disorder. Pfizer Inc. New York, NY, USA. (Data on file)
105. Fulton B, McTavish D. Fluoxetine: an overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 1995 Apr; 3: 305-22
106. Veivia AJ, Levin GM, Powell HS. Buspirone and sertraline in the treatment of a patient with refractory obsessive-compulsive disorder. J Pharm Technol 1995 Mar-Apr; 11: 50-2
107. Menkes DB. Buspirone augmentation of sertraline. Br J Psychiatry 1995 Jun; 166: 823-4
108. Doogan DP. Toleration and safely of sertraline: experience worldwide. Int Clin Psychopharmacol 1991 Dec: 6 Suppl. 2: 47-56
109. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997; 11 (1): 89-99
110. Lane R, Sweeney M, Henry JA. Pharmacotherapy of the depressed patient with cardiovascular or cerebrovascular illness. Br J Clin Pract 1994; 48: 256-62
111. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995; 9 (2 Suppl. I) 163-78
112. Fisch C, Knoebel SB. Electrocardiographic findings in sertraline depression trials. Drug Invest 1992; 4 (4): 305-12
113. Murdoch D, McTavish D. Sertraline. Curr Ther 1994 Jul; 35: 23-5
114. Lau GT, Horowitz BZ. Sertraline overdose. Acad Emerg Med 1996 Feb; 3: 132-6
115. Myers LB, Dean BS, Krenzelok EP. Sertraline (Zoloft®): over-dose assessment of a new antidepressant [abstract]. Vet Hum Toxicol 1993; 35: 341
116. Corkeron MA. Serotonin syndrome - a potentially fatal complication of antidepressant therapy. Med J Aust 1995 Nov 6; 163: 481-2
117. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
118. Braitberg G. Serotonin syndrome [letter]. Med J Aust 1994; 160: 527-8
119. Nierenberg DW, Semprebon M. The central nervous serotonin syndrome. Clin Pharmacol Ther 1993; 53: 84-8
120. Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses. Am J Emerg Med 1996; 14 (5): 456-8
121. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993 Mar; 12: 222-5
122. Sasson Y, Zohar J. New developments in obsessive-compulsive disorder research: implications for clinical management. Int Clin Psychopharmacol 1996; 11 Suppl. 5: 3-12
123. Anon. Inhibition of serolonin reuptake is the key to treating obsessive-compulsive disorder. Drug Ther Perspect 1993 Aug 30; 2 (4): 8-10